---
created: '2026-02-08T19:45:44.646437Z'
description: In a randomized, placebo-controlled, double-blind trial, NMN supplementation
  (250 mg/day for 10 weeks) increased skeletal muscle insulin sensitivity, insulin
  signaling, and muscle remodeling in postmenopausal prediabetic women. This represents
  a significant translational study demonstrating NAD+ precursor efficacy in human
  metabolic dysfunction.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/research/nmn-improves-muscle-insulin-sensitivity-in-prediabetic-women/
slug: nmn-improves-muscle-insulin-sensitivity-in-prediabetic-women
tags:
- research
- NMN
- NAD+
- insulin sensitivity
- skeletal muscle
- aging
- prediabetes
- clinical trial
title: NMN improves muscle insulin sensitivity in prediabetic women
type: research
updated: '2026-02-08T19:45:44.646437Z'
---

# NMN improves muscle insulin sensitivity in prediabetic women 
## Study Information
**Authors**: Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S**Journal**: Science
**Publication Date**: 2021-06-11
**Type**: Clinical Trial
**Study Design**: Randomized Controlled Trial**Citations**: 520**DOI**: [10.1126/science.abe9985](https://doi.org/10.1126/science.abe9985)**PMID**: [33888596](https://pubmed.ncbi.nlm.nih.gov/33888596/)**PMC**: [PMC8550608](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550608/)**Semantic Scholar**: [View](https://www.semanticscholar.org/paper/PMID:33888596)
## Abstract
In a randomized, placebo-controlled, double-blind trial, NMN supplementation (250 mg/day for 10 weeks) increased skeletal muscle insulin sensitivity, insulin signaling, and muscle remodeling in postmenopausal prediabetic women. This represents a significant translational study demonstrating NAD+ precursor efficacy in human metabolic dysfunction. 
## Keywords
NMN, NAD+, insulin sensitivity, skeletal muscle, aging, prediabetes, metabolic health, SIRT1
<!-- NEO4J_CONTENT_START -->
## Relationships
No relationships found.
<!-- NEO4J_CONTENT_END -->
## Methodology
```yaml
'{"blinding": "Double-blind (participants and investigators)", "design": "Randomized,
  placebo-controlled, double-blind trial", "intervention": "250 mg/day NMN or placebo
  for 10 weeks", "randomization": "Computer-generated randomization sequence"}'
```

### Study Design
- **Sample Size**: n=25- **Duration**: 10 weeks#### Population Characteristics
```yaml
'{"age_range": "55-75 years", "gender": "Female (postmenopausal)", "health_status":
  "Prediabetic, overweight or obese", "inclusion_criteria": ["BMI 25-40 kg/m2", "Prediabetic
  (HbA1c 5.7-6.4%)", "Postmenopausal"]}'
```

## Results
### Key Findings
```yaml
'{"primary": [{"measure": "Hyperinsulinemic-euglycemic clamp", "name": "Muscle insulin
  sensitivity", "p_value": 0.007, "result": "25% improvement in glucose disposal rate"}],
  "secondary": [{"name": "Muscle NAD+ content", "result": "Increased but not statistically
  significant"}, {"name": "Insulin signaling (AKT phosphorylation)", "result": "Significantly
  increased"}, {"name": "Muscle remodeling gene expression", "result": "Upregulated"}]}'
```

### Statistical Analysis
#### Statistical Significance
```yaml
'{"adjustment": "None required (single primary outcome)", "primary_outcome": "p =
  0.007 for glucose disposal rate"}'
```
#### Effect Sizes
```yaml
'{"confidence_interval": "95% CI: 8-42%", "glucose_disposal": "25% improvement (NMN
  vs placebo)"}'
```

## Limitations
- Small sample size (n=25)
- Female-only cohort limits generalizability
- Short duration (10 weeks)
- Single dose tested (250 mg/day)
- No long-term follow-up

## Research Integrity
### Funding Sources
- National Institutes of Health (NIH)
- Nutrition Obesity Research Center (Washington University)
### Conflicts of Interest
- S.I. Imai is co-inventor of patents related to NMN

## Replication Status
Partially replicated by subsequent studies (PMID: 35441613)

## References
- Rajman L et al. Cell Metab. 2018;27(3):529-547. PMID: 29514064
- Yoshino J et al. Cell Metab. 2011;14(4):528-536. PMID: 21982712
- Cant√≥ C et al. Cell Metab. 2012;15(6):838-847. PMID: 22682224

## Source Data
- **Source System:** PubMed - **Last Modified in Source:** 2026-01-25T21:22:09.479810+00:00